Dublin, December 22, 2020 (GLOBE NEWSWIRE) – Added Report “Global Market Report of Conjugated Monoclonal Antibodies 2020-30: Growth and Conversion of COVID-19” ResearchAndMarkets.com’s offering.
Global Conjugated Monoclonal Antibodies Market Report 2020-30: Growth and Conversion of COVID-19 provides the strategists, marketers and senior executives with the necessary information they need to evaluate on the global monoclonal antibodies market.
Key players in the market are concentrated monoclonal antibodies Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc. and Spectrum Pharmaceuticals Inc.
The global monoclonal antibodies market is expected to decline from $ 8.35 billion in 2019 to $ 8.15 billion in 2020 at a complex annual growth rate (CAGR) of -2.36%. The decline is largely due to the COVID-19 revolution that has led to limited containment measures including social distance, remote working, and the closure of businesses and other commercial activities leading to operational challenges. The entire supply chain was disrupted, adversely affecting the market. The market is then expected to recover and reach $ 10.41 billion in 2023 at a CAGR of 8.49%.
The conjugated monoclonal antibodies market includes the sale of condensed monoclonal antibodies. Concentrated monoclonal antibodies are monoclonal antibodies (mAbs) associated with chemotherapy drugs or radioactive grains. These are used in the treatment of cancer because they deliver the toxic substance directly to the tumor cells by reducing damage to the normal cells in other parts of the body.
North America was the largest segment in the conjugated monoclonal antibodies market in 2019.
In July 2020, AstraZeneca, a UK-based drugmaker, entered into a partnership with Daiichi Sankyo for a sum of $ 6 billion. This approval is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC), which is a type of drug that works by using a monoclonal antibody to deliver a linked drug-paying drug directly to tumor cells. Daiichi Sankyo is a Japanese-based pharmaceutical company involved in the development of a drug-antibody alliance.
The associated monoclonal antibodies market covered in this report is segmented by drugs into adcetris; kadcyla. It is also technologically separated to a portable binder; immobilized attachment and by exposure to blood cancer; breast cancer; ovarian cancer; lung cancer; brain tumors; others.
The high cost of condensed monoclonal antibodies is expected to hinder the growth of the condensed monoclonal antibodies market. For example, the first radioimmunotherapy drug approved by FDA Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $ 55,000. In addition, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas, approved in December 2019, costs between $ 110,000 to $ 120,000 for a course of treatment. The high cost of treatment makes it inaccessible to many patients and health care systems of underdeveloped countries, which hinders the growth of the market of concentrated monoclonal antibodies.
Companies operating in the related monoclonal antibodies market focus on strategic collaborations and partnerships. For example, in October 2019, NovoCodex, a subsidiary of Zhejiang Medicine Co. Ltd., collaborated for the second time with Ambrx Inc, a US-based company engaged in the development of protein medicine, for development and trade made the internally developed antibody-specific drug Ambrx developed internally. conjugate, ARX305 used for the treatment of advanced CD70 cancers.
Following the move, in June 2020, Monopar Therapeutics, a U.S.-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered into a collaboration to target the MNPR-101 Monopar, a human plasminogen urokinase receptor (uPAR) receptor target. monoclonal antibody at pre-IND level. , to the therapeutic radioisotope of NorthStar to create a highly selective agent, which has the ability to kill cytokine-producing immune cells.
The high popularity and therapeutic potential of condensed monoclonal antibodies specifically conjugate antibody-drug is expected to drive the market of concentrated monoclonal antibodies over the expected period. Conjugates of antibody drugs (ADCs) are a type of chemotherapy consisting of monoclonal antibodies (MAbs) collected by highly potent cytotoxic drugs through a binding mechanism to stimulate the antigen-expressing tumor cells killed, used mainly in the treatment of cancer.
The U.S. Food and Drug Administration approved just five drug alliance drugs from 2000 to 2018 and in 2019, they have approved three antibody-drug alliance drugs that reflect the increased number of licenses according to the amount of concentrated monoclonal antibodies mainly in the field of cancer, which itself contributes to the growth of the market.
Key topics covered:
1. Management Summary
2. Market characteristics of concentrated monoclonal antibodies
3. Market Size and Growth of Conjugated Monoclonal Antibodies
3.1. Global Conjugated Monoclonal Antibodies Market, 2015 – 2019, $ Billion
3.1.1. Market drivers
3.1.2. Market constraints
3.2. Global Antibodies Conjugated Antibodies Market Preview, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Market drivers
3.2.2. Market constraints
4. Market Seal of Conjugated Monoclonal Antibodies
4.1. Global Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historical and Foresight, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Conjugated Monoclonal Antibodies Market, Segmentation by Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Accessible connection
- Immovable connection
4.3. Global Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Blood cancer
- Breast cancer
- Ovarian Cancer
- Lung cancer
- Brain tumor
- Others
5. Regional and Rural Analysis of Conjugated Monoclonal Antibodies Market
5.1. Global Conjugated Monoclonal Antibodies Market, broken down by region, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Conjugated Monoclonal Antibodies Market, broken down by country, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies mentioned
- Pfizer Inc.
- F. Hoffmann-LA
- Bristol -Myers Squibb
- Merck & Co. Inc.
- Immunomedics Inc.
- Takeda Pharmaceuticals Ltd. Industries
- Daiichi Sankyo Company Limited
- Actinium Medication
- Nordic Nanovector Inc.
- Spectrum Pharmaceuticals Inc.
- AbbVie Inc.
- Roche Ltd
- Bayer AG
- AstraZeneca
- Novartis AG
For more information about this report, visit https://www.researchandmarkets.com/r/2oz9oa
Research and Markets also offers Custom Search services providing targeted, complete and unique search.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900